BI 764532 Dose Tolerance Study in DLL3-Positive Brain Tumor Patients Initiated
A clinical trial is underway to evaluate the tolerability of BI 764532 in adults with DLL3-positive brain tumors.
Therapeutic Area
Therapeutic area intelligence for CD3 Bispecific Antibody with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.